Naïve patients
(N=407)

Switch
(N=696)

Failure
(N=601)

Total
(N=1704)

Sex, N (%) men

295 (72.5)

483 (69.4)

398 (66.2)

1176 (69)

Age, median [Q1-Q3] years

41 [23.5-48]

44 [38-50]

42 [36-48]

43 [36-49]

Lenght of known infection, median [Q1-Q3] years

2 [0.3-7.8]

9.2 [4-14.6]

11.5 [6.6-16]

8.7 [2.9-14.5]

Hepatitis co-infection, N (%)

83 (20.4)

161 (23.1)

167 (27.8)

411 (24.1)

Previous CDC class C event, N (%)

85 (20.9)

209   (30)

179 (29.8)

473 (27.8)

Baseline VL, median [Q1-Q3] log10 copies/mL

4.8 [4.1 – 5.3]

1.6 [1.6 – 1.6]

3.9 [2.6 – 4.8]

2.5 [1.7 – 4.5]

Patients with baseline VL ≥ 5 log10 copies/mL (%)

41.2

-

18.5

15.1

Baseline CD4 cells/mm3, median [Q1-Q3]

239,2 [111-319]

512,4 [345-670]

286 [167-456]

354,7 [211-558]

Baseline CD4 cells <200/mm3 (%)

40.4

8.1

30.8

23

Nadir CD4 cells/mm3, median [Q1-Q3]

222 [104-289]

177 [71-264]

174 [64-261]

184 [74-272]

Number of previous regimens, median [Q1-Q3]

-

3 [1-5]

3 [2-5]

3 [3-5]

Treatment strategies

3 drugs in the regimen, N (%)

373 (92)

664 (95)

485 (81)

1522 (89)

ABC/3TC + 1 NNRTI, N (%)

36 (9)

241 (35)

49 (8)

326 (19)

ABC/3TC + 1 bPI, N (%)

211 (52)

279 (40)

301 (50)

791 (46)

ABC/3TC + AZT, N (%)

119 (29)

115 (16)

117 (19.5)

351 (21)

Other, N (%)

7 (2)

29 (4)

18 (3.5)

54 (3)

4 drugs or more in the regimen, N (%)

32 (8)

26 (4)

113 (19)

171 (10)

“Naïve patients”: ABC/3TC used as part of the first regimen, “switch”: as part of a switch strategy in patients with VL below detection, “failure” as part of a rescue regimen
in patients with a previous failing regimen; VL=viral load

Table 1: Patients characteristics at baseline.
Goto home»